In patients who have had Roux-en-Y gastric bypass surgery and have liver metastases, medications called somatostatin analogues do not lower low blood sugar levels, even though insulin levels are...
Mechanism
Synthesis from 1 study
After stomach surgery, the body makes too much insulin after meals, and that insulin keeps lowering blood sugar. Normally, a drug could stop this, but in these patients, the insulin-producing cells stop listening to the drug. The cells are overworked from too much stimulation, and now they don’t...
Most probable mechanism
After stomach surgery, the body releases too much insulin after eating, which lowers blood sugar. Normally, a drug like octreotide would calm down insulin production, but in this case, it doesn’t work — the insulin-producing cells no longer respond to the drug’s signal, even though the drug is present and the cells are still making too much insulin.
Roux-en-Y gastric bypass causes rapid delivery of nutrients to the small intestine, triggering exaggerated secretion of incretin hormones.
Excessive incretin signaling chronically overstimulates pancreatic beta cells, leading to sustained hyperinsulinemia.
Chronic overstimulation of beta cells alters somatostatin receptor expression or downstream signaling pathways, reducing responsiveness to somatostatin analogues.
Somatostatin analogues bind to somatostatin receptors on beta cells but fail to inhibit insulin secretion due to impaired signal transduction.
Persistently elevated insulin continues to drive glucose uptake into tissues and suppresses hepatic glucose production, resulting in hypoglycemia despite pharmacologic intervention.
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.